HMG-CoA reductase inhibitors (statins) versus placebo for people with schizophrenia

Yusuke Saishoji, Saehyeon Kim, Masahiro Banno, Kunihiro Kohmura, Yuki Kataoka, Yasushi Tsujimoto

Open source

DOI
10.1002/14651858.cd014565
Published
2025-09-19
Container
Cochrane Database of Systematic Reviews
Publisher
Wiley
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1002/14651858.cd014565,
  title = {HMG-CoA reductase inhibitors (statins) versus placebo for people with schizophrenia},
  author = {Yusuke Saishoji and Saehyeon Kim and Masahiro Banno and Kunihiro Kohmura and Yuki Kataoka and Yasushi Tsujimoto},
  year = {2025},
  journal = {Cochrane Database of Systematic Reviews},
  doi = {10.1002/14651858.cd014565},
  url = {https://doi.org/10.1002/14651858.cd014565}
}

RIS

TY  - JOUR
TI  - HMG-CoA reductase inhibitors (statins) versus placebo for people with schizophrenia
AU  - Yusuke Saishoji
AU  - Saehyeon Kim
AU  - Masahiro Banno
AU  - Kunihiro Kohmura
AU  - Yuki Kataoka
AU  - Yasushi Tsujimoto
PY  - 2025
JO  - Cochrane Database of Systematic Reviews
DO  - 10.1002/14651858.cd014565
UR  - https://doi.org/10.1002/14651858.cd014565
ER  - 

APA

Saishoji, Y., Kim, S., Banno, M., Kohmura, K., Kataoka, Y., & Tsujimoto, Y. (2025). HMG-CoA reductase inhibitors (statins) versus placebo for people with schizophrenia. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.cd014565

Source records